Randomized Trial Between Weekly and 5 Day 3 Weekly Cisplatin for Cervical Cancer

Inclusion Criteria:

• stage IB2-IVA , histological proven cervical carcinoma
• no previous diagnosis of carcinoma
• no prior history of chemotherapy or radiotherapy
• ECOG less than or equal to 2
• Above 21 years old
• medically fit for radical concurrent Cisplatin based chemotherapy and radiotherapy
• Hemoglobin >10g/dL

• Adequate hematological, renal and hepatic function according to all of the following laboratory values:

  • Absolute neutrophil count ≥ 1.5 ×109/l
  • Platelets ≥ 100 ×109/l
  • Serum creatinine ≤ 1.5 times upper limit of laboratory normal
  • Total serum bilirubin ≤ 1.5 times upper limit of laboratory normal
  • ASAT(AST) or ALAT(ALT) ≤ 2.5 times upper limit of laboratory normal
  • Alkaline phosphatase of ≤ 2.5 times upper limit of laboratory normal

Exclusion Criteria:

• Age below 21
• Presence of known HIV infection, chronic hepatitis B or hepatitis C infection
• Psychological, familial, sociological, or geographical condition that would preclude study participation
• Prior (within the last 3 years) or simultaneous malignancies (other then cutaneous basal cell carcinoma or non-invasive tumors)
• Patients with the following histologies are excluded: small cell, carcinoid, glassy cell, clear cell and adenoid cystic.
• Life expectancy < 6 months
• Patients with insulin dependent diabetes
• Prior tumor-directed surgery
• Previous systemic chemotherapy or pelvic radiation therapy
• As radiation and cytotoxic agents are contraindicated in pregnancy, pregnant women are ineligible and those of childbearing potential should use contraception